49
DAFTAR PUSTAKA
1. Kementrian Kesehatan Republik Indonesia. Pedoman Nasional Tatalaksana Klinis Infeksi HIV dan Terapi Antiretroviral pada orang dewasa. Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan. 2011.
2. Djoerban Z, Djauzi. HIV/AIDS di Indonesia. Dalam: Buku Ajar Ilmu Penyakit Dalam, Jilid III, Edisi V, Pusat Penerbit Departemen Ilmu Penyakit Dalam FKUI, Jakarta: 2009 November; 2861-8.
3. Dinkes Provinsi Sumatera Utara. Bidang Penanggulangan Penyakit Menular dan Penyehatan Lingkungan (P2MPL). Kasus HIV/AIDS 2013.
4. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents, Recommendations for a public health approach 2010.
5. Konsensus pengelolaan dislipidemia di Indonesia, PERKENI, 2012
6. Marisa T, Judith A. Dyslipidemia in HIV patients. Cleveland and Clinic Journal of Medicine. 2005. vol.72.p. 1113-20.
7. Eoin R. F and Patrick W. G. HIV and HAART-Associated Dyslipidemia. The Open Cardiovascular Medicine Journal, 2011, Volume 5.p.49-63.
8. Desy HP, Cita R, Hans L. Profil Lipid Penderita HIV/AIDS yang mendapat pengobatan ARV. Studi deskriptif observasional di Unit Perawatan Intermediet Penyakit Infeksi (PIPI) RSU Dr.Soetomo Surabaya.Abstrak. 2009.
9. Eric Walter PY, Awa Foueudjeu B, André Pascal K, François Jérome K & Jeanne N. First-line antiretroviral therapy and dyslipidemia in people living with HIV-1 in Cameroon: a cross-sectional study. AIDS Research and Therapy 2011; 8(33).
10. Périard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ, et.al. Atherogenic Dyslipidemia in HIV-Infected Individuals Treated With Protease Inhibitors. Circulation 1999;100:700-705.
11. RS Carling, R Hextall, PA DeSilva & JH Barth. Severe hypertriglyceridaemia associated with human immunodeficiency virus and highly active antiretroviral therapy. Annals of Clinical Biochemistry 2002; 39:409-411.
50
12. T.Oduola, A.A.Akinbolade, L.O.Oladokun, O.G.Adeosun, L.S.Bello and T.I.Ipadeola. Lipid Profiles in People living with HIV/AIDS on ARV Therapy in an Urban Area of Osun State, Nigeria. World Journal of Medical Sciences 2009; 4(1):18-21.
13. Buchacz K, Weidle PJ, Moore D, Were W, Mermin J, Downing R, et.al. Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr 2008; 47(3):304-11.
14. Domingo P, Labarga P, Palacios R, Guerreri MF, Terr´on JA, Eli´as MJP, et.al. Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results. AIDS 2004; 18(10):1475-8.
15. Tungsiripat M, Kitch D, Glesby MJ, Gupta SK, Mellors JW, Moran L, et.al. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206, AIDS 2010; 24(11):1781–1784.
16. Department of Health and Human Services Panel United States. The HIV Life Cycle. 2005.
17. Hoffmann C, Mulcahy F. ART 2007. HIV Medicine 2007. 15th edition. Paris: Flying Publisher; 2007; 1: 89-126.
18. Kirchner JT. Clinical Management Considerations for Dyslipidemia in HIV-Infected Individuals. Postgraduate Medicine 2012; 124(1):31-39.
19. Paulo RA, Fernando HW, Renato RO, Maria Letícia RI, Nêmora TB, Ajácio BM & Sandra CF. Metabolic syndrome and population attributable risk among HIV/AIDS patients: comparison between NCEP-ATPIII, IDF and AHA/NHLBI definitions. AIDS Research and Therapy 2012; 9:29.
20. Michael L.Green. Evaluation and Management of Dyslipidemia in Patients with HIV Infection. J.Gen Intern Med 2002;17:797-810.
21. Estrada V, Geijo P, Ferrer MF, Alcalde MLG, Rodrigo M, Galindo MJ, et.al. Dyslipidaemia in HIV-infected women on antiretroviral therapy. Analysis of 922 patients from the Spanish VACH cohort. BMC Women’s Health 2011; 11:36
51
22. Leonardo Calza, Roberto Manfredi and Francesco Chiodo. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. Journal of Antimicrobial Chemotherapy. 2004:53.p.10–14.
23. Up to date. Management of dyslipidemia and cardiovascular risk in the HIV-infected patient.
24. Sprinz E, Lazzaretti RK, Kuhmmer R, & Ribeiro JP. Dyslipidemia in HIV-infected individuals. Braz J Infect Dis 2010; 14(6):575-588.
25. Andrew carr, Cardiovascular risk factors in HIV-infected patients, . J Acquir Immune Defic Syndr. 2003: 34.S73-78.
26. Patrick W. G. Mallon, Antiretroviral Therapy and Dyslipidaemia: Unlocking the Code, www.plosmedicine.org, 2006, Volume 3, Issue 3, e85, p. 0291-3. 27. Tarr PE, Rotger M & Telenti A. Dyslipidemia in HIV- infected individuals :
from pharmacogenetics to pharmacogenomics. Pharmacogenomics 2010; 11(4):587–594.
28. Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)–Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Available from : http:// cid.oxfordjournals.org.
29. AIDS Education and Training Centers. Management of Dyslipidemia and HIV. Available from :http:// www.aidsetc.org.
30. Bennett M.T, Johns K.W and Bondy G.P. Current and Future Treatments of HIV-Associated Dyslipidemia. Future Lipidology.2008: 3(2).p. 175-188 31. Donald P. Kotler. HIV and Antiretroviral Therapy:Lipid Abnormalities and
Associated Cardiovascular Risk in HIV-Infected Patients,J Acquir ImmuneDeficSyndr 2008;49:S79-85.
32. Feeney ER & Mallon PWG. HIV and HAART-Associated Dyslipidemia. The Open Cardiovascular Medicine Journal 2011; 5:49-63.
33. Balasubramanyam A, Coraza I, Smith EO, Scott LW, Patel P, Iyer D, et.al. Combination of Niacin and Fenofibrate with Lifestyle Changes Improves Dyslipidemia and Hypoadiponectinemia in HIV Patients on Antiretroviral
52
Therapy: Results of “Heart Positive,” a Randomized, Controlled Trial. J Clin Endocrinol Metab 2011;96(7):2236–2247.
34. Calza L, Manfredi R & Chiodo F. Use of Fibrates in the Management of Hyperlipidemia in HIV- Infected Patients Receiving HAART. Infection 2002; 30:26-31.
35. Dahlan S. Langkah-langkah membuat proposal penelitian bidang kedokteran dan kesehatan. Sagung Seto. Seri 3 Edisi 2.
36. Ramezani A, Mohraz M, Yadegarinia D, Banifazl M, Gachkar L, Jam S, et.al. Prevalence of Dyslipidemia and Metabolic Abnormalities in HIV-Infected Patients. Acta Medica Iranica 2009; 47(2):83-88
37. Aragonès G, Villaverde CA, Reche PP, Rull A, Debón RB, Gallego ER,et.al. Antiretroviral treatment-induced dyslipidemia in HIV-infected patients is influenced by the APOC3-related rs10892151 polymorphism. BMC Medical Genetics 2011, 12:120.
38. Pujari SN.et.al.. Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India. J Acquir Immune Defic Syndr. 2005:39(2).p.199-202
39. Agete Tadewos, Zelalem Addis, Henock Ambachew and Sandip Banerjee, Prevalence of dyslipidemia among HIV-infected patients using first-line highly active antiretroviral therapy in Southern Ethiopia: a cross-sectional comparative group study, AIDS Research and Therapy 2012, 9:31
40. Armstrong C, Liu E, Okuma J, Spiegelman D, Guerino C, Njelekela M, et.al. Dyslipidemia in an HIV-positive antiretroviral treatment-naive population in Dar es Salaam, Tanzania. J Acquir Immune Defic Syndr 2011; 57(2):141-5. 41. Manuthu EM, Joshi, MD, Lule GN, et al. Prevalence of dyslipidemia in HIV
infected patients. East Afr Med J. 2008;85:10–17.
